# Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer or Other Solid Tumors

> **NCT05799274** · PHASE1 · RECRUITING · sponsor: **Radiopharm Theranostics, Ltd** · enrollment: 9 (estimated)

## Conditions studied

- Healthy Volunteers
- Pancreatic Ductal Adenocarcinoma
- Non-small Cell Lung Cancer (NSCLC)
- Esophageal Squamous Cell Carcinoma
- Cervical Cancer
- Endometrial Cancer
- Ovarian Cancer

## Interventions

- **DRUG:** RAD301 ([68Ga]-RAD301)

## Key facts

- **NCT ID:** NCT05799274
- **Lead sponsor:** Radiopharm Theranostics, Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-11-09
- **Primary completion:** 2026-05
- **Final completion:** 2026-05
- **Target enrollment:** 9 (ESTIMATED)
- **Last updated:** 2026-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05799274

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05799274, "Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer or Other Solid Tumors". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05799274. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*